← back to search

Adalgisa Condoluci

Ente Ospedaliero Cantonale · US
Area of research
Genetics · Pathology and Forensic Medicine
Research interest
Research interests include Chronic Lymphocytic Leukemia Research, Lymphoma Diagnosis and Treatment, Cancer Genomics and Diagnostics, and Immunodeficiency and Autoimmune Disorders.
h-index
16
citations
1,247
works
82
NIH funding
primary concept
Medicine
email

Recent publications

A comprehensive genetic study of classic Hodgkin lymphoma using circulating tumor DNA
Blood 2025cited by 13position: middledoi
CD49d expression is included in a revised 4‐factor model predicting outcome in patients with chronic lymphocytic leukemia treated with ibrutinib: A multicenter real‐world experience
HemaSphere 2024cited by 1position: middledoi
Genetic and phenotypic attributes of splenic marginal zone lymphoma
Blood 2021cited by 95position: middledoi
Assessment of the 4‐factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study
American Journal of Hematology 2021cited by 14position: middledoi
<scp><i>TP53</i></scp> disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases
American Journal of Hematology 2021cited by 13position: middledoi
Effectiveness of ibrutinib as first‐line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab‐bendamustine: Results of study on 486 cases outside clinical trials
American Journal of Hematology 2021cited by 3position: middledoi
International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia
Blood 2020cited by 137position: firstdoi
Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study
Leukemia 2020cited by 24position: middledoi
Comparison of ibrutinib and idelalisib plus rituximab in real‐life relapsed/resistant chronic lymphocytic leukemia cases
European Journal Of Haematology 2020cited by 7position: middledoi
External Validation of a Novel Risk Model (BALL Score) in Real-World Relapsed/Refractory Chronic Lymphocytic Leukemia Patients Receiving Ibrutinib. a Campus CLL Study
Blood 2019cited by 0position: middledoi
Impact of Smoking on Lung Cancer Treatment Effectiveness: A Review
Future Oncology 2016cited by 63position: firstdoi
Does prophylactic ligation of the thoracic duct reduce chylothorax rates in patients undergoing oesophagectomy? A systematic review and meta-analysis
European Journal of Cardio-Thoracic Surgery 2016cited by 54position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Ida Francesca Gallo · Università Campus Bio-Medico1 papers (2016–2016)Filippo Longo · Università Campus Bio-Medico1 papers (2016–2016)Giuseppe Mangiameli · Università Campus Bio-Medico1 papers (2016–2016)Giuseppe Tonini · Campus Bio Medico University Hospital1 papers (2016–2016)Tommasangelo Petitti · Università Campus Bio-Medico1 papers (2016–2016)Calogero Mazzara · Università Campus Bio-Medico1 papers (2016–2016)Pierfilippo Crucitti · Università Campus Bio-Medico1 papers (2016–2016)Aldo Pezzuto · Università Campus Bio-Medico1 papers (2016–2016)Alice Zoccoli · Università Campus Bio-Medico1 papers (2016–2016)Raffaele Rocco · Università Campus Bio-Medico1 papers (2016–2016)Gaetano Rocco · Memorial Sloan Kettering Cancer Center1 papers (2016–2016)